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Prognostication of ER-positive HER2-negative breast cancer is critical for 
decision making on adjuvant therapy. Many cancer patients are cured by local 
therapy, with surgery and radiotherapy, and endocrine therapy alone. 
Confidently identifying patients who are cured so they can safely avoid 
chemotherapy is essential to minimise overtreatment. Several commercially 
available gene expression genomic classifiers are available to help identify 
cancers that are at such low risk of recurrence, that chemotherapy could not 
provide a meaningful improvement in outcome.  
 
An unanswered question has been whether these genomic classifiers can give 
more information than just prognosis. In particular, can they confidently identify 
tumors that are insensitive to chemotherapy, such that even if the estimated risk 
of relapse based on clinicopathologic factors is sufficient to consider a course of 
chemotherapy, they can provide a classification that allows chemotherapy to be 
omitted from the patients’ management?  
 
Of the many genomic classifiers, the 21-gene Recurrence Score (RS; 
OncotypeDX), which has now been used in well over 500,000 patients1, had 
retrospective data from the NSABP B20 randomised trial of 
tamoxifen±chemotherapy that suggested that cancers with an old intermediate 
score (RS 18-30 and 10-year risk of distant recurrence of 11-21%) might be 
relatively insensitive to chemotherapy2. There has been uncertainty about the 
interpretation of that finding: it was derived from a retrospective, secondary 
analysis of a patient population that contributed samples to the training of the RS 
and the intermediate risk group comprised only 134 patients of which just 45 
were from the tamoxifen alone arm. In contrast to that small study, an EBCTCG 
overview analysis of about 100,000 patients, including about 10,000 randomised 
to anthracycline or no chemotherapy, found no difference in the proportional 
reductions in risk of recurrence between any subgroups including those defined 
by histopathologic grade, ER versus negativity or level of ER positivity3. The 
EBCTCG findings surprised many since they are in stark contrast with the strong 
correlations these markers show with response to chemotherapy in the 
neoadjuvant setting4. Oncologists regularly seeing patients responding or not to 
 3 
neoadjuvant chemotherapy according to these biologic factors may be receptive 
to the concept of molecular predictors of long-term benefit from adjuvant 
chemotherapy, while evidence for such differences is slim at best. 
 
The observation of possible prediction of chemotherapy sensitivity in the B20 
study was sufficiently important for the TAILORx study to be designed to test 
whether chemotherapy is beneficial for women with a new intermediate, or 
mid-range RS of 11 to 25 and who met National Comprehensive Cancer 
Network guidelines for the recommendation or consideration of adjuvant 
chemotherapy
5
. Yet for a variety of reasons TAILORx has not answered the 
question definitively. This raises a number of critical issues of more global 
importance to be considered for estimating risk in clinical practice and future 
clinical trial design. 
 
Many recent phase III adjuvant studies have reported lower event rates than 
predicted by historically based estimates, and have either extended their follow-
up time or increased the sample size; either way the population tested was of 
lower risk than expected6-9. It might have been anticipated that this would be 
minimal in TAILORx where modern molecularly based estimates of risk were a 
key entry criterion. Yet TAILORx presents one of the starkest examples of recent 
adjuvant trials.  The study was planned in anticipation of 87% 5-year invasive 
disease-free survival (iDFS; primary end-point) in the RS 11-25 group 
randomised to endocrine therapy only. Yet the 5-year iDFS was 92.8% and 5-
year distant metastasis-free survival was 98%. For the primary end-point, 59.5% 
of events were not related to the original cancer. The very substantial difference 
between anticipated events rates, and actual, may have reflected the very low 
risk patient population recruited: median 1.5cm tumor size, and 86% low-
intermediate grade.  
 
The low breast cancer event rate for the study challenges the interpretation of its 
results. With 98% of patients in the endocrine only arm being free from distant 
recurrence at 5 years, the study has not been able to address whether 
intermediate risk cancers are chemotherapy sensitive, the original objective of 
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the study. Instead patients in the randomized population recruited had such a 
good prognosis, chemotherapy was irrelevant. This is a very positive outcome 
for patients, with node-negative disease and tumors similar to those recruited 
into the randomised part of the study but it poses challenges to the 
generalizability of the finding to patients with higher stages of disease. 
 
Most importantly, it is clear that integration of clinical parameters and molecular 
scores improves the accuracy of prognostic estimates. Indeed the much lower 
than expected relapse rate could potentially have been anticipated in the 
randomised population to TAILORx, if clinical factors had been integrated into 
the estimate of risk. An earlier study found that only about 5% of the variability 
in risk estimates made by Adjuvant Online was explained by estimates by 
OncotypeDX10. This prompted a study that combined data from NSABP-14 and 
TransATAC on patients treated with only endocrine therapy to create the RS-
pathology-clinical (RSPC)11. The RSPC included RS, age, tumor size, grade and 
type of hormonal treatment and provided a risk estimate that provided 
significantly improved prognostic value over RS alone. Strikingly, only 28% of 
the 385 patients that had an intermediate RS (18-30) were characterised as 
intermediate risk by RSPC, while 55% of that group were downstaged by RSPC to 
low risk. The importance of integrating certain clinical factors with genomic 
prognostic scores is recognised by other genomic predictors such as Endopredict 
and ProSigna, in which tumor size is automatically integrated with molecular 
risk. It is also important to note that the type of endocrine therapy is important, 
and yet test results do not factor this in; the relative risk of breast cancer 
mortality on an aromatase inhibitor is approximately 15% lower than with 
tamoxifen12. Notably, while the MINDACT trial did not fully integrate clinical and 
molecular scores it created four categories according to high/low risk for both 
clinical and molecular features13.  
 
The data from TAILORx suggest that the traditional definition of iDFS is no 
longer the best end-point for clinical trials. Including occurrence of new cancers 
of any type in the definition, which are very unlikely to be affected by the 
randomisation, resulted in 35% of the events in the primary endpoint, greater 
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than the number of distant recurrences. New definitions of iDFS without second 
cancers may become a standard for future studies. 
 
TAILORx also demonstrates the limitation of non-inferiority study designs for 
low risk populations. Although TAILORx technically demonstrated non-
inferiority of endocrine therapy versus chemotherapy and endocrine therapy for 
mid-range RS (five year iDFS hazard ratio 1.08; 95% confidence interval, 0.94 to 
1.24; P = 0.26), this may have been the result of the low breast cancer event rate, 
and high number of non-breast cancer events in the primary endpoint. This has 
important implications for applying the result to stage II (and stage III) breast 
cancers, where the benefit from chemotherapy for these cancers of intermediate 
score has not yet been answered. The ongoing RxPONDER study will address this 
for node-positive disease (NCT01272037). 
 
There are implications for future studies in low risk patient populations. A 
cohort study may be able to change clinical practice, if a well-characterised 
cohort can be derived that will show sufficiently good outcome to negate benefit 
from additional treatment. This was demonstrated by the extremely low event 
rates of the low risk (RS<11) TAILORx population14. Similarly, the 98.7% 3-year 
iDFS of a cohort of patients with small HER2+ tumours treated with paclitaxel 
and trastuzumab excludes meaningful benefit from adding more toxic 
chemotherapeutics15. Such cohort studies will likely report many years earlier 
than non-inferiority studies. Additionally, if the cancer event-rate in a non-
inferiority trial is substantially lower than anticipated, the study may not 
address the original objective. It is therefore highly important to ensure the risk 
profile of patients recruited will give the anticipated event rate, with the data 
monitoring committee primed to monitor this. 
 
A particularly striking subgroup analysis in TAILORx identified a large benefit for 
chemotherapy in young patients with intermediate risk scores above 15. The 
potential pitfalls of unplanned retrospective subgroup analysis in clinical trials 
are well documented, most eloquently first demonstrated in the ISIS-2 trial, 
where astrological star sign associated with benefit from aspirin after a 
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myocardial infarction16. Examples are frequently observed in cancer trials; for 
example patients with HER2-positive non-visceral disease derived no benefit 
from pertuzumab in overall survival in the CLEOPATRA trial17. Such chance 
observations are frequent in subgroup analyses. 
 
Of note the young patient subgroup analysis in TAILORx was retrospective, not 
pre-planned, and presents one subgroup (age) further subdivided by ranges of 
RS (11-15, 16-20 and 21-25). The analysis suggested that premenopausal 
patients with an RS of 16 or greater may in contrast to the rest of the randomised 
population derive benefit from chemotherapy5. Yet the number of distant 
recurrences in the <=50 RS subgroups is very small, 16, 27 and 26 events 
respectively. We suggest that this should be considered a hypothesis-generating 
result. The Oxford EBCTCG meta-analyses in unselected patients, with many 
thousands of events, suggests moderately worse prognosis for young women, 
and modestly greater benefit from chemotherapy, but no major differences 
compared to older women18. Chemotherapy induced menopause in the <50 age 
group may also have contributed to the observed effect, as the study pre-dated 
the SOFT and TEXT studies demonstrating the benefit of ovarian suppression in 
premenopausal women8,9..   
 
What does a practicing clinician do with the results of the TAILORx study? We 
expect this to be the subject of future guidelines, and we give our view as an 
interim measure. 
 
Firstly, risk estimates from molecular factors should be considered together with 
standard clinico-pathologic factors (tumor size, grade, nodes, age, type of 
endocrine therapy) and not in isolation. Without integration, a clinician may 
decide to offer chemotherapy to a patient with a 10mm ER positive cancer with a 
RS of 27 (high risk score by TAILORx), and not offer chemotherapy for a 40mm 
ER positive cancer with a RS of 23 (intermediate risk score by TAILORx). Yet the 
second patient is at substantially greater risk of relapse, and likely to derive 
substantially more benefit from chemotherapy. The tools to integrate clinical 
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features with Oncotype are readily available18 and clinicians using Oncotype may 
wish to consider using them routinely.  
 
Secondly, to derive chemotherapy benefit estimates from combined molecular 
and clinical risk the following should be considered. Stage I and II, lymph node-
negative ER-positive cancers </=3cm with a low risk score have such a low event 
rate to not require chemotherapy5,14  Similarly, TAILORx demonstrates that stage 
I cancers with an intermediate risk have such a low risk of recurrence they could 
not benefit from chemotherapy. Yet, the chemotherapy sensitivity of stage II/III 
cancers with intermediate risk has not been answered as yet. Oxford overview 
data3 suggests that third generation adjuvant chemotherapy reduced the risk of 
mortality by approximately 35% allowing estimates of chemotherapy benefit 
from RSPC.  
 
Thirdly, for cancers with intermediate scores and higher clinical risk, 
chemotherapy may still be appropriate as discussed above. The TAILORx study 
recruited very few patients with tumors greater than 3cm, and no patients with 
node positive tumors; the RxPONDER study will address node positive patients.  
 
Lastly, as noted above it is well-documented that women of young age, have a 
higher risk of relapse and overall a modestly greater benefit from 
chemotherapy19. Beyond this, there is no strong data to suggest that cancers of 
intermediate risk 21-gene RS have fundamentally different sensitivity to 
chemotherapy in young versus older women.  Age should therefore be factored 
into decisions about chemotherapy, but should not be a major driver in decision-
making. Premenopausal patients with intermediate risk should likely be 
considered for ovarian suppression8,9. 
 
In summary and conclusion, the TAILORx study has been one of the most 
ambitious and important biomarker studies conducted in oncology. The study 
re-emphasises the ability to avoid chemotherapy in most stage I ER-positive 
HER2-negative cancers, and aids in our decision making in stage II cancers with 
tumour sizes up to 3cm. Most importantly the study stresses the critical 
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importance of integrating molecular and clinical risk in routine practice, eg with 
RSPC. This general issue should be factored into routine clinical care; clinical 
trial design may then encompass better powering and meet the trial’s objectives 
within targeted recruitment and contemporary clinical practise. 
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